Eugia Pharma Specialities Limited Meropenem Export Data — India (DGFT 2022–2026)

Name: Eugia Pharma Specialities Limited Meropenem Export Records India — #2 Exporter, 341 Shipments, $17.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Meropenem

India Pharmaceutical Trade Intelligence

$222.9M401 Suppliers134 CountriesHS 30049099

ExportsIndia → BELGIUM32.0%India → UNITED STATES15.5%

ImportsSWITZERLAND → India$418.3M BELGIUM → India$257.7K

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: YUSEN LOGISTICS

Eugia Pharma Specialities Limited — Meropenem Exporter #2 | $17.1M Trade Value | TransData Nexus | TransData Nexus

Eugia Pharma Specialities Limited — Meropenem Exporter Profile

Indian Pharmaceutical Exporter · #2 for Meropenem · $17.1M export value · DGFT Verified

Eugia Pharma Specialities Limited is the #2 Indian exporter of Meropenem with $17.1M in export value and 341 verified shipments. Eugia Pharma Specialities Limited holds a 7.6% market share in Meropenem exports across 18 countries. The company exports 49 pharmaceutical products worth $170.1M across 14 therapeutic categories.

Eugia Pharma Specialities Limited — Meropenem Export Profile: Buyers & Destinations

Eugia Pharma Specialities Limited Meropenem export treemap — buyers and destination countries | TransData Nexus

Where Does Eugia Pharma Specialities Limited Export Meropenem?

Country	Value	Shipments	Share
UNITED STATES	$8.2M	163	53.0%
MEXICO	$1.5M	34	10.0%
BRAZIL	$1.3M	30	8.8%
MALTA	$1.2M	27	7.5%
CANADA	$934.5K

Who Are the Top Buyers of Meropenem from Eugia Pharma Specialities Limited?

Buyer	Country	Value	Orders
EUGIA US LLC,	UNITED STATES	$4.1M	82
EUGIA US LLC	UNITED STATES	$2.1M	43
AUROMEDICS PHARMA, LLC,	UNITED STATES	$1.6M	32
AUROVIDA FARMACEUTICA SA DE CV	MEXICO	$991.2K	23
AUROMEDICS PHARMA, LLC.	UNITED STATES	$600.0K	12
EUGIA PHARMA ( MALTA) LTD.	MALTA	$500.0K	10
EUGIA PHARMA (MALTA) LTD,	MALTA	$406.9K	12
AURO PHARMA INC	CANADA	$400.0K	8
EUGIA PHARMA INDUSTRIA	BRAZIL	$400.0K	8
LIMITADA, VIA PRINCIPAL 06E, SN,	BRAZIL	$348.5K	9

Eugia Pharma Specialities Limited supplies Meropenem to 59 buyers globally. The largest buyer is EUGIA US LLC, (UNITED STATES), followed by EUGIA US LLC (UNITED STATES) and AUROMEDICS PHARMA, LLC, (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Meropenem Formulations Does Eugia Pharma Specialities Limited Export?

Product Description / Formulation	Value	Shipments
MEROPENEM FOR INJECTION 1 G/VIAL (Merope	$2.1M	42
MEROPENEM FOR INJECTION 1G/VIAL(MEROPEN	$650.0K	13
MEROPENEM FOR INJECTION 500 MG/VIAL(Mero	$450.0K	9
MEROPENEM FOR INJECTION 500 MG/VIAL (Mer	$400.0K	8
MEROPENEM FOR INJECTION 1 G/VIAL (MEROPENEM 1G)	$270.2K	6
MEROPENEM FOR INJECTION 1G/VIAL (Meropen	$200.0K	4
MEROPENEM F.INJ. 1G/VIAL(MEROPENEM 1000	$200.0K	4
MEROPENEM FOR INJECTION 500 MG/VIAL,(MER	$200.0K	4
MEROPENEM FOR INJECTION 1 G/VIAL(MEROPEN	$150.0K	3
MEROPENEM FOR INJECTION 500 MG/VIAL(MER	$150.0K	3

Eugia Pharma Specialities Limited exports 196 distinct Meropenem formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MEROPENEM FOR INJECTION 1 G/VIAL (Merope with 42 shipments worth $2.1M.

How Does Eugia Pharma Specialities Limited Compare to Nearest Meropenem Exporters?

Exporters ranked immediately above and below #2 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
3	VENUS REMEDIES LIMITED	$40.0M	801	41	$50.0K
2	EUGIA PHARMA SPECIALITIES LIMITED ★	$17.1M	341	18	$50.0K
1	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$10.3M	206	16	$50.0K
5	BROOKS STERISCIENCE LIMITED	$2.3M	45	9	$50.0K

Eugia Pharma Specialities Limited ranks #2 among 401 Indian Meropenem exporters. Average shipment value of $50.0K compared to the market average of $200.8K. The closest competitors by value are VENUS REMEDIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Which Indian Ports Ship Meropenem Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	504	13.8%
DELHI AIR	494	13.5%
SAHAR AIR	256	7.0%
SAHAR AIR CARGO ACC (INBOM4)	246	6.7%
NHAVA SHEVA SEA (INNSA1)	233	6.4%
CMA CGM LOGISTICS PARK ICD (INCPL6)	198	5.4%
Delhi Air	103	2.8%
DHANNAD ICD (INDHA6)	94	2.6%

Geopolitical & Trade Policy Impact on Eugia Pharma Specialities Limited's Meropenem Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Eugia. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended transit times. These logistical hurdles are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in supply chain management. (pharmaceuticalcommerce.com)

Conversely, U.S.-China trade tensions have opened avenues for Indian exporters. With the U.S. seeking to diversify its supply chains away from China, Indian pharmaceutical companies have the opportunity to capture a larger share of the U.S. market. Eugia's recent FDA approvals and product launches position it well to capitalize on this shift.

However, the imposition of new tariffs by the U.S. administration in August 2025, affecting over 60 countries including India, poses a significant challenge. These tariffs, reaching up to 39%, could impact nearly 55% of India's exports to the U.S., including pharmaceuticals. The increased cost burden may erode profit margins and affect competitiveness in the U.S. market. (apnews.com)

In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement. Indian exporters must ensure stringent adherence to serialization and traceability standards to maintain access to the EU market. Eugia's commitment to quality and regulatory compliance will be pivotal in navigating these regulatory landscapes.

Eugia Pharma Specialities Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the USFDA intensifying inspections and compliance requirements. Eugia's experience with the USFDA's warning letter for its Unit-III facility underscores the importance of robust quality management systems. Addressing these regulatory observations is crucial for maintaining market access and reputation.

Indian pharmaceutical companies, including Eugia, are investing in upgrading manufacturing practices to meet international standards. This proactive approach is essential to mitigate risks associated with non-compliance and to sustain growth in regulated markets.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Meropenem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Eugia Pharma Specialities Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 341 individual customs records matching Eugia Pharma Specialities Limited exporting Meropenem, covering 196 formulations to 20 countries via 59 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 134+ countries, 966+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Meropenem

Meropenem

Eugia Pharma Specialities Limited — Meropenem Exporter Profile

Eugia Pharma Specialities Limited — Meropenem Export Profile: Buyers & Destinations

Where Does Eugia Pharma Specialities Limited Export Meropenem?

Who Are the Top Buyers of Meropenem from Eugia Pharma Specialities Limited?

What Is India's Total Meropenem Export Value and How Much Does Eugia Pharma Specialities Limited Contribute?

What Is the Average Shipment Value for Eugia Pharma Specialities Limited's Meropenem Exports?

How Does Eugia Pharma Specialities Limited Compare to Other Indian Meropenem Exporters?

What Meropenem Formulations Does Eugia Pharma Specialities Limited Export?

Regulatory Requirements: Exporting Meropenem to Key Markets

United States — FDA

Mexico — COFEPRIS

Brazil — ANVISA

How Does Eugia Pharma Specialities Limited Compare to Nearest Meropenem Exporters?

Which Indian Ports Ship Meropenem Exports?

What Other Advanced Antibiotics Products Does Eugia Pharma Specialities Limited Export?

Meropenem — Export Intelligence Video

Geopolitical & Trade Policy Impact on Eugia Pharma Specialities Limited's Meropenem Exports

Eugia Pharma Specialities Limited — Regulatory Compliance & Quality Standards

About Eugia Pharma Specialities Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Meropenem Export Data from Eugia Pharma Specialities Limited

Meropenem Stats

Company Overview

Top Products by Eugia Pharma Specialities Limited

Related Analysis

Need Detailed Export Data?

Data Source